Thalia Therapeutics (LSE:THAT) OCF Margin %: -17,925.00% (As of Dec. 2025)


What is Thalia Therapeutics OCF Margin %?

Thalia Therapeutics LSE:THAT +17.39% OCF Margin % is -17,925.00% as of Dec. 2025. The stock has 3 warning signs investors should review. Among 960 Biotechnology companies, Thalia Therapeutics ranks worse than 94.79% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Thalia Therapeutics's Cash Flow from Operations for the six months ended in Dec. 2025 was £-0.72 Mil. Thalia Therapeutics's Revenue for the six months ended in Dec. 2025 was £0.00 Mil. Therefore, Thalia Therapeutics's OCF Margin % for the quarter that ended in Dec. 2025 was -17,925.00%.

As of today, Thalia Therapeutics's current OCF Yield % is -21.42%.

The historical rank and industry rank for Thalia Therapeutics's OCF Margin % or its related term are showing as below:

LSE:THAT' s OCF Margin % Range Over the Past 10 Years
Min: -60450   Med: -13885.71   Max: -32.55
Current: -14512.5

During the past 13 years, the highest OCF Margin % of Thalia Therapeutics was -32.55%. The lowest was -60450.00%. And the median was -13885.71%.

LSE:THAT's OCF Margin % is ranked worse than
94.79% of 960 companies
in the Biotechnology industry
Industry Median: -68.59 vs LSE:THAT: -14512.50

Thalia Therapeutics OCF Margin % Related Terms

Thalia Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Thalia Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thalia Therapeutics OCF Margin % Chart

Thalia Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -60,450.00 -13,885.71 -16,585.71

Thalia Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -29,050.00 -9,775.00 -19,366.67 -11,100.00 -17,925.00

LSE:THAT vs VRTX, REGN, ALNY: OCF Margin % Comparison

For the Biotechnology subindustry, Thalia Therapeutics's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Thalia Therapeutics OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Thalia Therapeutics's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Thalia Therapeutics's OCF Margin % falls into.


Thalia Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Thalia Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-1.161/0.007
=-16,585.71 %

Thalia Therapeutics's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-0.717/0.004
=-17,925.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -17,925.00% mean?
Thalia Therapeutics (LSE:THAT) has a OCF Margin % of -17,925.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Thalia Therapeutics and its competitors. According to the industry distribution chart, Thalia Therapeutics ranks #910 out of 960 companies in the Biotechnology industry, placing it in the top 94.8%.
Is Thalia Therapeutics' OCF Margin % too high?
Thalia Therapeutics' current OCF Margin % is -17,925.00%. Based on the distribution chart, Thalia Therapeutics ranks #910 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Thalia Therapeutics' OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Thalia Therapeutics ranks #910 out of 960 companies for OCF Margin %. This places Thalia Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Thalia Therapeutics and its competitors. Thalia Therapeutics's current OCF Margin % is -17,925.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thalia Therapeutics stock overvalued right now?
Thalia Therapeutics (LSE:THAT) has a current OCF Margin % of -17,925.00%. The current OCF Margin % is -17,925.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Thalia Therapeutics (LSE:THAT), the current OCF Margin % is -17,925.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Thalia Therapeutics Business Description

Other Exchanges 0GO:Germany
Address 2 Portman Street, London, GBR, W1H 6DU
Thalia Therapeutics PLC is a biotechnology company developing RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. Its pipeline includes a long-duration, dual-acting siRNA program targeting PCSK9 and lipoprotein(a) [Lp(a)], which are established risk factors for cardiovascular disease.